Pyridones

"Pyridones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Pyridine derivatives with one or more keto groups on the ring.

Descriptor ID	D011728
MeSH Number(s)	D03.383.725.791
Concept/Terms	Pyridones Pyridones Pyridinones

Below are MeSH descriptors whose meaning is more general than "Pyridones".

Chemicals and Drugs [D]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, 1-Ring [D03.383]
Pyridines [D03.383.725]
Pyridones [D03.383.725.791]

Below are MeSH descriptors whose meaning is more specific than "Pyridones".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Pyridones" by people in this website by year, and whether "Pyridones" was a major or minor topic of these publications.

Bar chart showing 31 publications over 16 distinct years, with a maximum of 4 publications in 2013

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2004	0	1	1
2007	1	0	1
2009	0	1	1
2013	3	1	4
2014	1	1	2
2015	1	1	2
2016	1	2	3
2017	3	0	3
2018	1	2	3
2019	1	1	2
2020	0	1	1
2021	1	0	1
2022	0	1	1
2023	1	2	3
2024	0	1	1
2025	0	2	2

Below are the most recent publications written about "Pyridones" by people in Profiles.

Richeldi L, Azuma A, Cottin V, Kreuter M, Maher TM, Martinez FJ, Oldham JM, Valenzuela C, Clerisme-Beaty E, Gordat M, Wachtlin D, Liu Y, Schlecker C, Stowasser S, Zoz DF, Wijsenbeek MS. Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis. N Engl J Med. 2025 Jun 12; 392(22):2193-2202.

View in: PubMed
Gramatica A, Miller IG, Ward AR, Khan F, Kemmer TJ, Weiler J, Huynh TT, Zumbo P, Kurland AP, Leyre L, Ren Y, Klevorn T, Copertino DC, Chukwukere U, Levinger C, Dilling TR, Linden N, Board NL, Falling Iversen E, Terry S, Mota TM, Bedir S, Clayton KL, Bosque A, MacLaren Ehui L, Kovacs C, Betel D, Johnson JR, Paiardini M, Danesh A, Jones RB. EZH2 inhibition mitigates HIV immune evasion, reduces reservoir formation, and promotes skewing of CD8+ T cells toward less-exhausted phenotypes. Cell Rep. 2025 May 27; 44(5):115652.

View in: PubMed
Shankar DA, Hawkins F, Alysandratos KD, Wilson KC, Walkey AJ, Bosch NA, Law AC. Uptake of Antifibrotics for Patients with Idiopathic Pulmonary Fibrosis: 2016-2022. Ann Am Thorac Soc. 2024 Jan; 21(1):170-173.

View in: PubMed
Hwang YJ, Chang HY, Metkus T, Andersen KM, Singh S, Alexander GC, Mehta HB. Risk of Major Bleeding Associated with Concomitant Direct-Acting Oral Anticoagulant and Clopidogrel Use: A Retrospective Cohort Study. Drug Saf. 2024 Mar; 47(3):251-260.

View in: PubMed
Kim JS, Murray S, Yow E, Anstrom KJ, Kim HJ, Flaherty KR, Martinez FJ, Noth I. Comparison of Pirfenidone and Nintedanib: Post Hoc Analysis of the CleanUP-IPF Study. Chest. 2024 May; 165(5):1163-1173.

View in: PubMed
de Andrade JA, Neely ML, Hellkamp AS, Culver DA, Kim HJ, Liesching T, Lobo LJ, Ramaswamy M, Safdar Z, Bender S, Conoscenti CS, Leonard TB, Palmer SM, Snyder LD. Effect of Antifibrotic Therapy on Survival in Patients With Idiopathic Pulmonary Fibrosis. Clin Ther. 2023 04; 45(4):306-315.

View in: PubMed
Janardhan HP, Dresser K, Hutchinson L, Trivedi CM. Pathological MAPK activation-mediated lymphatic basement membrane disruption causes lymphangiectasia that is treatable with ravoxertinib. JCI Insight. 2022 09 08; 7(17).

View in: PubMed
Eshleman SH, Fogel JM, Piwowar-Manning E, Chau G, Cummings V, Agyei Y, Richardson P, Sullivan P, Haines CD, Bushman LR, Petropoulos C, Persaud D, Kofron R, Hendrix CW, Anderson PL, Farrior J, Mellors J, Adeyeye A, Rinehart A, St Clair M, Ford S, Rooney JF, Mathew CA, Hunidzarira P, Spooner E, Mpendo J, Nair G, Cohen MS, Hughes JP, Hosseinipour M, Hanscom B, Delany-Moretlwe S, Marzinke MA. Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084. J Infect Dis. 2022 05 16; 225(10):1741-1749.

View in: PubMed
Delany-Moretlwe S, Hughes JP, Bock P, Ouma SG, Hunidzarira P, Kalonji D, Kayange N, Makhema J, Mandima P, Mathew C, Spooner E, Mpendo J, Mukwekwerere P, Mgodi N, Ntege PN, Nair G, Nakabiito C, Nuwagaba-Biribonwoha H, Panchia R, Singh N, Siziba B, Farrior J, Rose S, Anderson PL, Eshleman SH, Marzinke MA, Hendrix CW, Beigel-Orme S, Hosek S, Tolley E, Sista N, Adeyeye A, Rooney JF, Rinehart A, Spreen WR, Smith K, Hanscom B, Cohen MS, Hosseinipour MC. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022 05 07; 399(10337):1779-1789.

View in: PubMed
Bugide S, Gupta R, Green MR, Wajapeyee N. EZH2 inhibits NK cell-mediated antitumor immunity by suppressing CXCL10 expression in an HDAC10-dependent manner. Proc Natl Acad Sci U S A. 2021 07 27; 118(30).

View in: PubMed

People

Explore

Similar Concepts

Top Journals